Company intelligence / Profile preview
Integrated BioTherapeutics
- Ownership
- Private
- Employees
- ~44
- Development stage
- Phase 1
Overview
IBT’s lead vaccine product against Staphylococcus aureus (“IBT-V02”) has completed cGMP manufacturing and IND-enabling studies with clinical trials anticipated. The company received a $16.3M NIH contract to develop a monoclonal antibody for Marburg virus disease supporting manufacturing and a Phase 1 trial. Other programs are at preclinical or IND-enabling stages
- Therapeutic areas
- Infectious Diseases
- Modalities
- monoclonal antibodies (mAbs)vaccinesimmunotherapies
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Integrated BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Integrated BioTherapeutics.